| Autor: |
Salem, Mohamed, Bendary, Ahmed, Moustafa, Shaimaa, Ramzy, Ahmed, Sanad, Osama |
| Zdroj: |
Egyptian Heart Journal; Mar2014, Vol. 66 Issue 1, p43-48, 6p |
| Abstrakt: |
Abstract: Objectives: To test the safety of sildenafil in patients with stable coronary artery disease (CAD). Methods: Sixty-one patients with stable CAD, documented by coronary angiography were included in this phase I study. Patients were randomized to either single dose sildenafil or matched placebo. Speckle tracking echocardiography was done at baseline and 60min after sildenafil/placebo intake to calculate peak systolic strain (PSS) of the most severely affected myocardial segments and the global longitudinal PSS. Results: The baseline mean segmental PSS in the sildenafil group changed by 52%, −3±1% at baseline versus −7±2% after sildenafil intake, P =0.01. However, no significant changes were reported in the placebo group, −7±3% at baseline versus −7.25±3%, P =0.1. The baseline mean global longitudinal PSS in the sildenafil group changed by 9% (−15±4% at baseline versus −18±3% after sildenafil, P =0.03). In placebo patients, the change was only 3% from baseline (−14.8±2% at baseline compared to −15±2% after placebo intake, P =0.1). Sildenafil was well tolerated without clinical or hemodynamic deterioration after its intake. Conclusion: Sildenafil intake is safe in patients with stable CAD, it induced marginal improvements in the peak systolic strain of different myocardial ischemic territories. [Copyright &y& Elsevier] |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
